Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
Open Forum Infectious Diseases
|
May 29, 2020
Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
Thomas Lodise, Sam Colman, Daniel S Stein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 19, 2005
Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections
Luis E Jauregui, Simon Babazadeh, Elyse Seltzer, et al.
Journal of Public Health Management and Practice : JPHMP
|
October 12, 2014
Factors associated with uptake of the Influenza A(H1N1)pdm09 monovalent pandemic vaccine in K-12 Public Schools, Maine 2009-2010
Suchita A Lorick, Lisa Goldberg, Fan Zhang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 6, 2019
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
Thomas M File, Lisa Goldberg, Anita Das, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 19, 2019
Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
Thomas M File, Lisa Goldberg, Anita Das, et al.
JAMA
|
September 28, 2019
Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial
Elizabeth Alexander, Lisa Goldberg, Anita F Das, et al.
Journal of Global Antimicrobial Resistance
|
November 17, 2021
Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin
Susanne Paukner, Lisa Goldberg, Elizabeth Alexander, et al.
Nutrition Research Reviews
|
November 29, 2021
A synthesis of pathways linking diet, metabolic risk and cardiovascular disease: a framework to guide further research and approaches to evidence-based practice
Marjorie Rafaela Lima do Vale, Luke Buckner, Claudia Gabriela Mitrofan, et al.
Brain : a Journal of Neurology
|
February 27, 2018
Mechanistic basis of an epistatic interaction reducing age at onset in hereditary spastic paraplegia
Timothy Newton, Rachel Allison, James R Edgar, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
Open Forum Infectious Diseases
|
May 29, 2020
Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
Thomas Lodise, Sam Colman, Daniel S Stein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 19, 2005
Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections
Luis E Jauregui, Simon Babazadeh, Elyse Seltzer, et al.
Journal of Public Health Management and Practice : JPHMP
|
October 12, 2014
Factors associated with uptake of the Influenza A(H1N1)pdm09 monovalent pandemic vaccine in K-12 Public Schools, Maine 2009-2010
Suchita A Lorick, Lisa Goldberg, Fan Zhang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 6, 2019
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
Thomas M File, Lisa Goldberg, Anita Das, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 19, 2019
Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
Thomas M File, Lisa Goldberg, Anita Das, et al.
JAMA
|
September 28, 2019
Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial
Elizabeth Alexander, Lisa Goldberg, Anita F Das, et al.
Journal of Global Antimicrobial Resistance
|
November 17, 2021
Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin
Susanne Paukner, Lisa Goldberg, Elizabeth Alexander, et al.
Nutrition Research Reviews
|
November 29, 2021
A synthesis of pathways linking diet, metabolic risk and cardiovascular disease: a framework to guide further research and approaches to evidence-based practice
Marjorie Rafaela Lima do Vale, Luke Buckner, Claudia Gabriela Mitrofan, et al.
Brain : a Journal of Neurology
|
February 27, 2018
Mechanistic basis of an epistatic interaction reducing age at onset in hereditary spastic paraplegia
Timothy Newton, Rachel Allison, James R Edgar, et al.
Page
of 4